OM Pharma
Script error: No such module "AfC submission catcheck".
 | |
| Société Anonyme | |
| ISIN | 🆔 |
| Industry | Biopharmaceutical |
| Founded 📆 | Barcelona, (1930) |
| Founder 👔 | |
| Headquarters 🏙️ | Geneva, Switzerland |
Area served 🗺️ | Worldwide |
Key people |
|
| Products 📟 | OM-89 |
| Owner | Etienne Jornod (Executive Chairman & Co‑Owner) |
| Members | |
Number of employees | |
| 🌐 Website | www |
| 📇 Address | |
| 📞 telephone | |
OM Pharma is a Swiss multinational biopharmaceutical company headquartered in Geneva.
OM Pharma was originally founded in Barcelona in 1930 and later moved its headquarters to Geneva in 1937 under the leadership of Jean-René Ricard, a French Pharmacist. In 2020, the company was acquired by Optimus Holding, led by Etienne Jornod, which committed to significant investments in its research and manufacturing capabilities[1][2][3].
The company specialises in the development and commercialization of bacterial lysate-based products., aimed at preventing respiratory and urinary tract infections by training the immune system[4]. OM Pharma's pipeline focuses on future applications of lysates.
In 2021, OM Pharma was awarded the Geneva Economy Award[5]. The independent jury noted OM Pharma’s economic and social policy which aims at the long-term development of the company; all its profits are reinvested in research and development (R&D)[6][7].
History[edit]
Incorporation into CSL Vifor/Galenica[edit]
In 1970, the company re-established its main base of operations in Meyrin, where it continues to operate to this day. In 2009, the family-owned business was acquired by Galenica[8], part of the Vifor Pharma Group[9][10]
Acquisition by Optimus Holding[edit]
In 2020, OM Pharma underwent a change in ownership when Optimus Holding, led by former Vifor Pharma Executive Chairman Etienne Jornod, acquired the company.[11][12]
This transaction re-established OM Pharma as an independent entity and included a commitment from Optimus Holding to invest over CHF 250 million into expanding the company's manufacturing and research capabilities[13]. The current CEO since 2024 is Roch Ogier[14].
Structure and subsidiaries[edit]
OM Pharma employs over 400 people, with its Global Headquarters and Biotech Campus located in Meyrin, Geneva, as well as an affiliate in Villars-sur-Glane, Fribourg[15].
The company also has a presence in Peru through an affiliate in Lima[16][17] and maintains a dedicated sales force in Central America, covering Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama, and the Dominican Republic.[18]
Additionally, OM Pharma has a presence in Shanghai to support its business partners across the Asia-Pacific region.[19]
Partners[edit]
OM Pharma has a network of global partners who market and distribute OM Pharma products. Partners range from local, family owned to multinational entities.[20]
Research areas and products[edit]
OM Pharma is known for the development of bacterial lysate products (OM-85 and OM-89) manufactured on its site in Meyrin, Geneva[21]. The company also markets small molecules for the treatment of vascular diseases globally[22].
Globally marketed products[edit]
- Broncho Vaxom® is an immunomodulator and bacterial lysate (OM-85) of 21 bacterial strains used for the prevention of recurrent respiratory tract infections[23].
- Uro Vaxom® is an immunomodulator and bacterial lysate (OM-89) of 18 strains of Escherichia coli for the treatment and prevention of recurrent urinary tract infections.
- Dicynone® (etamsylate) is indicated in the treatment of capillary haemorrhages of different origins such as heavy menstrual bleeding or surgeries affecting highly vascularised tissues.
- Doxium® (calcium dobesilate) is used for the oral treatment of microangiopathies, signs of chronic venous insufficiency in the lower limbs, diabetic retinopathy and haemorrhoidal syndrome.
References[edit]
- ↑ "Interview avec Etienne Jornod | Board Talk". Deloitte Switzerland (in français). Retrieved 2024-10-30.
- ↑ "Etienne Jornod achète une deuxième fois OM Pharma à Genève - Le Temps" (in français). 2020-09-18. ISSN 1423-3967. Retrieved 2024-10-30.
- ↑ "Etienne Jornod, président d'OM Pharma à Genève: «Il ne faut pas baisser le prix des médicaments de façon linéaire» - Le Temps" (in français). 2024-12-13. ISSN 1423-3967. Retrieved 2024-12-18.
- ↑ Leo (2022-02-17). "List of the 3 largest chemical companies from Geneva (Canton)". Research Germany. Retrieved 2024-10-30.
- ↑ "OM Pharma Wins Geneva Economy Award". PharmExec. 2021-09-21. Retrieved 2024-11-13.
- ↑ "La Gazette du LABORATOIRE - OM Pharma remporte le Prix 2021 de l'économie genevoise". www.gazettelabo.fr. Retrieved 2024-11-13.
- ↑ Hernandez, Miguel (2021-09-21). "Le Prix 2021 de l'économie genevoise attribué à OM Pharma" (in français). Retrieved 2024-11-13.
- ↑ "Galenica acquiert la société biotech OM Pharma - Le Temps" (in français). 2009-09-08. ISSN 1423-3967. Retrieved 2024-11-01.
- ↑ BioAlps, Admin (2021-10-20). "BioAlps | 20 years of innovation | OM Pharma". BioAlps. Retrieved 2024-10-30.
- ↑ "économie - L'entreprise compte 65 % de frontaliers parmi ses 200 collaborateurs. OM Pharma, rescapée genevoise de la pharmaceutique, a 80 ans". www.ledauphine.com (in français). Retrieved 2024-11-01.
- ↑ Oviedo de Valeria, Jenny (1994-08-02). "chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/http://www.revista-educacion-matematica.org.mx/descargas/vol6/vol6-2/vol6-2-5.pdf". Educación matemática. 6 (2): 73–86. doi:10.24844/em0602.06. ISSN 2448-8089.
- ↑ "Etienne Jornod, président d'OM Pharma à Genève: «Il ne faut pas baisser le prix des médicaments de façon linéaire» - Le Temps" (in français). 2024-12-13. ISSN 1423-3967. Retrieved 2024-12-18.
- ↑ PricewaterhouseCoopers. "Vifor Pharma Group announces successful sale of OM Pharma to Optimus Holding Ltd". PwC. Retrieved 2024-10-30.
- ↑ "La Gazette du LABORATOIRE - OM Pharma nomme Roch Ogier au poste de CEO". www.gazettelabo.fr. Retrieved 2024-11-01.
- ↑ "Redevenue indépendante, OM Pharma vise les Etats-Unis - Le Temps" (in français). 2024-12-13. ISSN 1423-3967. Retrieved 2024-12-18.
- ↑ "OM Pharma situa su filial peruana como hub regional para Latinoamérica". PMFarma. Retrieved 2024-10-30.
- ↑ GESTIÓN, NOTICIAS (2023-05-03). "Farmacéutica | OM Pharma sitúa hub regional en Perú, las razones detrás y negocios a la vista | ECONOMIA". Gestión (in español). Retrieved 2024-11-01.
- ↑ "Cartography of the Geneva Health Hub - Health field concerned - Pharmacy - OM Pharma". platform.genevahealthforum.com. Retrieved 2024-10-30.
- ↑ "OM Pharma opens a new office in Shanghai - OM Pharma | OM Pharma". www.ompharma.com. Retrieved 2024-10-30.
- ↑ "Nouveaux licenciements en série chez OM Pharma". Tribune de Genève (in français). 2023-10-27. Retrieved 2024-11-01.
- ↑ "Economie romande. OM Pharma, perle industrielle genevoise, s'ouvre les portes de l'Amérique du Nord - Le Temps" (in français). 2007-06-14. ISSN 1423-3967. Retrieved 2024-11-01.
- ↑ "Redevenue indépendante, OM Pharma vise les Etats-Unis - Le Temps" (in français). 2024-12-13. ISSN 1423-3967. Retrieved 2024-12-18.
- ↑ Dang, A. T.; Pasquali, C.; Ludigs, K.; Guarda, G. (2017-03-06). "OM-85 is an immunomodulator of interferon-β production and inflammasome activity". Scientific Reports. 7 (1): 43844. Bibcode:2017NatSR...743844D. doi:10.1038/srep43844. ISSN 2045-2322. PMID 28262817.
This article "OM Pharma" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:OM Pharma. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
